1168-P: Complications in the Second Year of LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India
Authors: RAIS NADEEM , DAS ASHOK K. , JOSHI SHASHANK , MITHAL AMBRISH , KALRA SANJAY , UNNIKRISHNAN AMBIKA GOPALAKRISHNAN , THACKER HEMANT , SETHI BIPIN , CHOWDHURY SUBHANKAR , NAIR ARJUN , MOHANASUNDARAM SENTHILNATHAN , MENON SHALINI K. , SALVI VAIBHAV , CHODANKAR DEEPA , TRIVEDI CHIRAG , WANGNOO SUBHASH KUMAR , ZARGAR ABDUL H. , KUMAR K.M. PRASANNA 
Published: May 2022

Macrovascular and microvascular complications were evaluated during the first 2 years of LANDMARC, a 3-year prospective observational study (CTRI/2017/05/008452) that included participants with T2D on ≥2 antihyperglycemic medications. Out of 6234 evaluable participants (mean baseline values - age: 52.1 years, T2D duration: 8.59 years and A1C: 8.05%) , 5318 participants completed the 2-year follow-up. The mean A1C decreased by 0.58% (baseline: 8.05%) in 2 years. The microvascular complications were frequent in 17.6% participants (1096/6234) ; while the incidence of macrovascular complications was 1.1% participants (66/6234) . Neuropathy was the most commonly reported complication (baseline: 11.8% and 2-years: 14.4%) . Overall, complications were more common in participants with BMI ≥23 kg/m2, A1C ≥7% or having CV risk factors (Table) . A total of 41 deaths were reported; of which 30 deaths were attributed to CV causes (sudden death [n=19], myocardial infarction [n=9], stroke [n=1], and coronary artery procedure [n=1]) . The 2-year results indicate more complications among those who were overweight, or with suboptimal glycemic control or having CV risk factors. Neuropathy was the predominant T2D complication. These results offer insights into disease progression and suggest the need for controlling risk factors and timely treatment adjustment in participants with T2D.

Disclosure

N. Rais: None. A.K. Das: Advisory Panel; Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Diagnostics, Sanofi. Speaker's Bureau; Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Inc., USV Private Limited. S. Joshi: Advisory Panel; Abbott, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Novo Nordisk, Roche Diabetes Care. Consultant; Biocon, Glenmark Pharmaceuticals, Sanofi, USV Private Limited. A. Mithal: Advisory Panel; Eris Lifesciences Ltd. Consultant; Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Inc., USV Private Limited. Speaker's Bureau; Abbott Diabetes, AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., Novartis AG, Novo Nordisk, Sanofi. S. Kalra: Speaker's Bureau; Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Sanofi. A. Unnikrishnan: Advisory Panel; Intas Pharmaceuticals Ltd. Speaker's Bureau; Abbott, AstraZeneca, Boehringer-Ingelheim, Sanofi. Other Relationship; Novo Nordisk, Serdia Pharmaceuticals (India) Pvt. Ltd., Torrent Pharmaceuticals Ltd. H. Thacker: None. B. Sethi: None. S. Chowdhury: None. A. Nair: None. S. Mohanasundaram: Employee; Sanofi. V. Salvi: Employee; Sanofi. D. Chodankar: Employee; Sanofi. C. Trivedi: None. S. Wangnoo: None. A.H. Zargar: Advisory Panel; Sanofi. Speaker's Bureau; AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Novo Nordisk, USV Private Limited. K. Kumar: None.

Funding

Sanofi, India